about
How can we standardize peritoneal thickness measurements in experimental studies in rats?Endogenous testosterone and mortality in male hemodialysis patients: is it the result of aging?The link between bone and coronary calcifications in CKD-5 patients on haemodialysisThe impact of membrane permeability and dialysate purity on cardiovascular outcomesHigher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size.Magnesium reduces calcification in bovine vascular smooth muscle cells in a dose-dependent manner.The relationship between renal volume and histology in obese and nonobese kidney donors.Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis.Role of asymmetric dimethylarginine in the progression of carotid atherosclerosis in renal transplant patients.Risk factors and consequences of post-transplant diabetes mellitus.[Tuberculin skin test reactivity in patients with chronic renal failure].The influence of dialysate calcium on progression of arterial stiffness in peritoneal dialysis patients.The benefit of salt restriction in the treatment of end-stage renal disease by haemodialysis.Does enalapril prevent peritoneal fibrosis induced by hypertonic (3.86%) peritoneal dialysis solution?Successful treatment of post-transplant Kaposi's sarcoma by reduction of immunosuppression.Correlation between serum YKL-40 (chitinase-3-like protein 1) level and proteinuria in renal transplant recipients.The associations between serum paraoxonase 1 activity and carotid atherosclerosis in renal transplant patients.Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients.The relationships between serum sTWEAK, FGF-23 levels, and carotid atherosclerosis in renal transplant patients.Relation between serum estradiol levels and mortality in postmenopausal female hemodialysis patients.Relationship between glucose exposure via peritoneal dialysis solutions and coronary artery calcification in non-diabetic peritoneal dialysis patients.Effect of fluid management guided by bioimpedance spectroscopy on cardiovascular parameters in hemodialysis patients: a randomized controlled trial.Carbamylated low-density lipoprotein induces proliferation and increases adhesion molecule expression of human coronary artery smooth muscle cells.What does peritoneal thickness in peritoneal dialysis patients tell us?Neither oxidized nor anti-oxidized low-density lipoprotein level is associated with atherosclerosis or mortality in hemodialysis patients.Comparison of 4- and 8-h dialysis sessions in thrice-weekly in-centre haemodialysis: a prospective, case-controlled study.Planning a social activity to improve psychological well-being and quality of life of hemodialysis patients: a pilot study.Effects of three times weekly eight-hour nocturnal hemodialysis on volume and nutritional status.Epicardial adipose tissue volume and cardiovascular disease in hemodialysis patients.Pre-transplant HbA1c level as an early marker for new-onset diabetes after renal transplantation.Effects of thrice weekly nocturnal hemodialysis on arterial stiffness.The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients.The effect of immunosuppressive treatment on arterial stiffness and matrix Gla protein levels in renal transplant recipients.Long-term survival rates in haemodialysis patients treated with strict volume control.FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients.High-dose immunoglobulin therapy in renal transplant recipients with hemophagocytic histiocytic syndrome.Nephrosclerosis and carotid atherosclerosis: Lessons from kidney donor histologyIs “zero-hour” biopsy of the transplanted kidney risky?Glycated hemoglobin predicts overall and cardiovascular mortality in non-diabetic hemodialysis patientsCan strict volume control be the key for treatment and prevention of posterior reversible encephalopathy syndrome in hemodialysis patients?
P50
Q30826483-840EA744-DCBC-4935-8D85-E27E970113A3Q34405392-515C7902-D0AE-4AE4-A361-6AB6DA403EACQ35025415-B48A41CD-5FA4-4A93-8CC8-5B661D94C05EQ36880441-3835D0D5-1D01-4470-8202-11156053A323Q40559660-827A2C74-D7F4-4235-8A66-932B2541F5D8Q40963199-2CBEBFB1-DB10-47BF-8419-052423A035D6Q42174540-D73B14A0-BE13-423C-8A3D-74C14F8C15C0Q42371213-61D2A764-97BF-43A8-A4F1-E42F8435EB6BQ42986982-C6117811-9DE0-40F0-A016-D2371BBEAE10Q42996266-88AD4B94-B5F3-4C28-9B97-DCFA4AB84030Q43269887-12414D70-5356-4748-9A75-CA1770F29132Q43487330-DB48DA0B-5D8B-4750-BD16-3ED9145A307EQ43516185-267060A3-444A-4DC8-A729-EFA288326973Q43593390-D84C70AC-213F-47B7-B1F1-D2A9013FF00BQ43974311-54134793-DCF4-4E79-A07F-1B5F04F21BF4Q44976848-AB22468A-E9EC-4C2A-A253-6FDB9A21371FQ45087266-1B9E1EA7-CC47-4C78-8F76-A8F1F5927C19Q45934981-B40B45CD-3998-4FC0-8223-A7C9D7D0831CQ45953803-CB99E61C-E8E5-436F-AA7F-6FCE554A00A6Q46081928-E4FFAC31-43A0-443E-8AAB-8A773C2D7D30Q46123279-47452EDB-29E1-4A40-8953-FA5BCE4E0619Q46150453-B039BECD-AA1D-408D-B207-5E29DDD88657Q46563174-91702731-D1EA-45B5-8EB9-F76410E4C644Q46988240-F50A45C2-9B9B-4EA0-ACD6-1FD8F76E472CQ47911686-D2448D5B-BAB2-4D9A-B26C-275DF8C07207Q48730803-57D874EA-9D7A-43A4-97A2-F50BF304312BQ49072333-DAF44816-6B25-4C9D-B0B4-D5BA6110763FQ50937582-C4269870-0E14-4F31-B097-84204686C476Q51295908-03770888-CD6B-40A5-8006-00CCAF254A8CQ51304497-2460B611-2296-4E6B-B68E-A22F35851AAEQ51375264-4AF8F1AD-1103-4D5E-A6E0-6AE15294F47CQ51435548-85B4C253-C767-4CBE-A89B-722FF86605F1Q51459064-A42AA29C-18FD-4C3F-834B-6D769BF66CDFQ51784628-1169EA24-1FBE-465A-800A-9BEBA5711654Q52985054-5A85B76B-C6C5-4CB3-B6DE-ABD77E3E115BQ54458776-BA6B66B7-C5EC-4AAE-A738-DCA8B3BCEA05Q58024471-843520A2-D208-484B-B846-FEA28C618879Q58024514-CC5DD7AE-3005-493A-B87F-9F119DF5ACEAQ62085736-744B6A17-CADC-416D-9D0D-99AA04A75FCAQ62085749-2D00BA40-5024-47F9-97DF-E7304AD129FF
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Gulay Asci
@ast
Gulay Asci
@en
Gulay Asci
@es
Gulay Asci
@nl
Gulay Asci
@sl
type
label
Gulay Asci
@ast
Gulay Asci
@en
Gulay Asci
@es
Gulay Asci
@nl
Gulay Asci
@sl
prefLabel
Gulay Asci
@ast
Gulay Asci
@en
Gulay Asci
@es
Gulay Asci
@nl
Gulay Asci
@sl
P106
P21
P31
P496
0000-0001-5582-6430